GLS and ovarian carcinoma: Increased GLS1 expression in a variety of human cancer types was associated with significantly decreased patient survival, which suggests its function as a potential prognostic biomarker for many human cancers, including hepatocellular carcinoma (HCC), ovarian cancer, osteosarcoma, colorectal cancer (CRC) and breast cancer (64, 81–85).